| dc.description.abstract | Introduction: Salbutamol sulfate is a sympatomymetic bronchodilator (β2 agonist), a selective, specific bronchodilation that causes direct relaxation of the smooth muscles of the bronchial wall. Treatment reversible obstructive airways, chronic and acute asthma, bronchitis, emphysema, acute bronchial asthma and other obstructive pulmonary diseases and prevention of exercise-induced bronchospasm are prescribed. Common side effects can be cardiac arrhythmias and overuse causes bronchospasm. Having to optimize inhalation performance the properties of the formulation, which can reduce the dose and side effects.
Objective: The purpose of this study is to provide an effective inhaler form of salbutamol sulfate.
Method: By dissolving the drug powder in a suitable solvent with a specific ratio and injection of the solution into the crystallization bath and throwing the solution with air pressure to the heating column, we were able to collect the crystalline microcrystalline drug in the metal plates. The micronized particles of the drug were mixed in different forms with a certain ratio of lactohil in turbomixers, and the final formulation was obtained. The properties of dry inhalation powder characterized by X-ray diffraction devices (XRD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and inductor (NGI) were investigated.
Results: The inhalable dry powder of salbutamol sulfate prepared by an ultrasonic atomizer has a particle size of 1 to 5 micrometres, which was confirmed by SEM. XRD and DSC tests show crystalline reduction properties. In a 6-month sustainability study, powder has retained a low-crystalline property. The results of the evaluation of the ability to inhale powder supplied with the NGI 24% FPF = device showed that FPF is an acceptable range for dry inhaler powder.
Conclusion: We devised a new method for the preparation of DPI. This method is applicable to the preparation of a variety of drugs in the future. | en_US |
